Rarity Bioscience is headed to the Biomarkers 2024 UK conference in London, to present how the superRCA technology expands the
1 mutation in 100 000 wild-types because sensitivity matters
Radically improving cancer diagnostics
Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.